Cyclerion Therapeutics Files 8-K: Material Agreement
Ticker: CYCN · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1755237
| Field | Detail |
|---|---|
| Company | Cyclerion Therapeutics, Inc. (CYCN) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1,250,000 b, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
Cyclerion signed a material definitive agreement on 12/13/24. Details to follow.
AI Summary
On December 13, 2024, Cyclerion Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Massachusetts and its principal executive offices are located at 245 First Street, 18th Floor, Cambridge, MA 02142.
Why It Matters
This 8-K filing indicates a significant new agreement for Cyclerion Therapeutics, which could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities that are not yet fully understood.
Key Numbers
- 001-38787 — SEC File Number (Identifies the specific SEC filing for Cyclerion Therapeutics, Inc.)
- 83-1895370 — IRS Employer Identification Number (Tax identification number for the company.)
Key Players & Entities
- Cyclerion Therapeutics, Inc. (company) — Registrant
- December 13, 2024 (date) — Date of earliest event reported
- December 17, 2024 (date) — Date of Report
- Massachusetts (location) — State of incorporation
- 245 First Street, 18th Floor, Cambridge, Massachusetts 02142 (address) — Principal executive offices
FAQ
What is the nature of the Material Definitive Agreement entered into by Cyclerion Therapeutics, Inc. on December 13, 2024?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on December 13, 2024.
What are the key items disclosed in this 8-K filing?
This 8-K filing discloses an Entry into a Material Definitive Agreement, Regulation FD Disclosure, and Financial Statements and Exhibits.
Where are Cyclerion Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Cyclerion Therapeutics, Inc. are located at 245 First Street, 18th Floor, Cambridge, Massachusetts 02142.
What is the state of incorporation for Cyclerion Therapeutics, Inc.?
Cyclerion Therapeutics, Inc. is incorporated in Massachusetts.
What is the SEC file number for Cyclerion Therapeutics, Inc.?
The SEC file number for Cyclerion Therapeutics, Inc. is 001-38787.
Filing Stats: 791 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-12-17 08:16:57
Key Financial Figures
- $1,250,000 b — ia has agreed to pay to the Company (i) $1,250,000 before December 31, 2024, and (ii) $500,0
- $500,000 — ,000 before December 31, 2024, and (ii) $500,000 on or before September 30, 2025. In add
Filing Documents
- d856941d8k.htm (8-K) — 29KB
- d856941dex101.htm (EX-10.1) — 40KB
- d856941dex991.htm (EX-99.1) — 9KB
- g856941g1216163553183.jpg (GRAPHIC) — 5KB
- 0001193125-24-280125.txt ( ) — 220KB
- cycn-20241213.xsd (EX-101.SCH) — 3KB
- cycn-20241213_lab.xml (EX-101.LAB) — 18KB
- cycn-20241213_pre.xml (EX-101.PRE) — 11KB
- d856941d8k_htm.xml (XML) — 4KB
FINANCIAL STATEMENTS AND EXHIBITS
FINANCIAL STATEMENTS AND EXHIBITS. EXHIBIT INDEX Exhibit Number Exhibit Title 10.1 Amendment #1 to License Agreement by and between the Company and Akebia Therapeutics, Inc. dated December 13, 2024 99.1 Press release dated December 17, 2024, titled "Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Registrant has omitted portions of Exhibit 10.1 as permitted under Item 601(b)(10) of Regulation S-K. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cyclerion Therapeutics, Inc. Dated: December 17, 2024 By: /s/ Regina Graul, Ph.D. Name: Regina Graul, Ph.D. Title: President and Chief Executive Officer (Principal Executive Officer) 3